The main needs of the pharmaceutical industry are as follows. Reduce the number of molecular candidates, decrease the failure rate by cheap simulation, and use less experiments in the first stage of the drug R&D.
a) Progress beyond the state of the art
We have made a commitment to enable fast and precise simulations by two features. The first one is the selected precise simulation method (QC is based on physical first principles) was made available to run on GPUs. The second one is the fact that our highly specialized framework makes the calculation of high impulse moment orbitals (like f, g and h) available.
These features make our project unique. The availability of these high impulse orbitals are necessary to be able to simulate chemical bond formation and breaking in biologically relevant molecules and systems.
In order to increase the performance of our simulator we added the CPU as a computing device as well. In this way both the GPU and the CPU cores are utilized as much as possible. This CPU-GPU hybrid is also a highly innovative solution in the field of QC.
b) expected results and impacts
The previously listed facts and results make available the usage of QC simulations as a powerful tool within the pharmaceutical industry. These simulations can achieve the desired precision, can work together with other simulation methods, available to a wide scale of systems, flexible and experimentally validated. The introduction of QC was blocked by the trendemous computational time that is reduced by two orders of magnitude with our software module. As a consequence the main economical benefit of our product is the shortening of the phase of basic research during pharmaceutical drug research. This means cheaper and faster time to market. The advantages of our simulation tool will consequently result more frequent launch of new, more efficient and cheaper medicines, which would bring a significant change especially for Europe’s aging society.